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Abstract
Background: The Lung Cancer Exercise Training Study (LUNGEVITY) is a randomized trial to investigate the efficacy of 
different types of exercise training on cardiorespiratory fitness (VO2peak), patient-reported outcomes, and the organ 
components that govern VO2peak in post-operative non-small cell lung cancer (NSCLC) patients.
Methods/Design: Using a single-center, randomized design, 160 subjects (40 patients/study arm) with histologically 
confirmed stage I-IIIA NSCLC following curative-intent complete surgical resection at Duke University Medical Center 
(DUMC) will be potentially eligible for this trial. Following baseline assessments, eligible participants will be randomly 
assigned to one of four conditions: (1) aerobic training alone, (2) resistance training alone, (3) the combination of 
aerobic and resistance training, or (4) attention-control (progressive stretching). The ultimate goal for all exercise 
training groups will be 3 supervised exercise sessions per week an intensity above 70% of the individually determined 
VO2peak for aerobic training and an intensity between 60 and 80% of one-repetition maximum for resistance training, 
for 30-45 minutes/session. Progressive stretching will be matched to the exercise groups in terms of program length 
(i.e., 16 weeks), social interaction (participants will receive one-on-one instruction), and duration (30-45 mins/session). 
The primary study endpoint is VO2peak. Secondary endpoints include: patient-reported outcomes (PROs) (e.g., quality of 
life, fatigue, depression, etc.) and organ components of the oxygen cascade (i.e., pulmonary function, cardiac function, 
skeletal muscle function). All endpoints will be assessed at baseline and postintervention (16 weeks). Substudies will 
include genetic studies regarding individual responses to an exercise stimulus, theoretical determinants of exercise 
adherence, examination of the psychological mediators of the exercise - PRO relationship, and exercise-induced 
changes in gene expression.
Discussion: VO2peak is becoming increasingly recognized as an outcome of major importance in NSCLC. LUNGEVITY 
will identify the optimal form of exercise training for NSCLC survivors as well as provide insight into the physiological 
mechanisms underlying this effect. Overall, this study will contribute to the establishment of clinical exercise therapy 
rehabilitation guidelines for patients across the entire NSCLC continuum.
Trial Registration: NCT00018255
Background
Improvements in surgical techniques together with more
effective adjuvant chemotherapeutic regimens has led to
significant survival benefit for individuals with non-small
cell lung cancer (NSCLC). Approximately 26,000 individ-
uals per year in the United States will survive more than 5
years after initial diagnosis of operable disease. With
improving prognosis, acute and long-term disease - and
treatment-related morbidity (symptom control) and mor-
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tality are now recognized as issues of major clinical
importance in the multidisciplinary management of
operable NSCLC [1-6]. A parameter of central impor-
tance that may mediate acute and late-occurring disease
and treatment-related toxicity in lung cancer survivor-
ship is cardiorespiratory fitness. Cardiorespiratory fit-
ness, as measured by an objective exercise tolerance test,
reflects the integrative capacity of components in the
oxygen (O2) cascade to supply adequate O2 for adenosine
triphosphate (ATP) resynthesis. Peak oxygen consump-
tion (VO2peak) provides the gold standard (direct) assess-
ment of cardiorespiratory fitness. Direct or estimated
measurement of cardiorespiratory fitness is a well-estab-
lished independent predictor of mortality in a broad
range of non-cancer, adult populations [7,8].
Not surprisingly, operable NSCLC patients have signifi-
cant and marked reductions in VO2peak. Postsurgical
NSCLC patients are subject to the effects of normal age-
ing, age-related and/or disease-related comorbid condi-
tions, and deconditioning that adversely impact
components of the O2 cascade. However, these 'normal'
consequences are profoundly accelerated by disease
pathophysiology and the use of conventional adjuvant
therapy to create a 'perfect deconditioning storm', reduc-
ing either the body's ability to deliver and/or utilize O2
and substrate leading to poor VO2peak[9]. Such effects
have important implications across the entire NSCLC
continuum[10].
First, preoperative VO2peak  is a well-established risk
stratification tool to determine perioperaitve and postop-
erative complication risk [11-14]. Second, following
resection, VO2peak as well as self-reported exercise behav-
ior (a major determinant of VO2peak), are strong predic-
tors of patient-reported outcomes (PROs) such as overall
QOL, fatigue, and other QOL domains[15]. Finally, our
group found that pre-operative VO2peak is a strong inde-
pendent predictor of overall survival in NSCLC surgical
candidates even when controlling for performance status,
gender, and age[16]. In totality, these data provide strong
evidence that VO2peak is an attractive modifiable thera-
peutic target to improve surgical risk and/or recovery,
symptom control and possibly, disease outcome in
NSCLC.
Chronic, repeated aerobic training (i.e., continuous
activity involving large muscle groups) is widely estab-
lished as the most effective method to improve VO2peak in
healthy humans although a paucity of studies have inves-
tigated the role of exercise in NSCLC[10]. Given the pre-
liminary nature of this field, we recently completed two
uncontrolled pilot studies investigating the feasibility and
preliminary efficacy of supervised aerobic training in the
pre-operative and post-operative setting in NSCLC.
Results of these pilot studies provided 'proof of principle'
that aerobic training is a safe and feasible intervention for
NSCLC patients, however, the improvements in VO2peak
were modest (<15%), particularly in the post-operative
setting (~10%) despite good exercise adherence rates
(≥70% of planned sessions) [17,18].
The reasons for the relatively modest improvement in
VO2peak in NSCLC relative to other clinical populations
(i.e., ~15%-20% improvement in VO2peak following tradi-
tional aerobic training recommendations) remain to be
elucidated. An obvious potential explanation is a ventila-
tory limitation or inadequate gas exchange following
removal of a substantial portion of lung parenchyma.
However, several elegant studies have demonstrated that
VO2peak is not limited by ventilation or diffusion capacity
[19-22] suggesting that exercise-induced adaptations (or
lack thereof) in the other organ components of the O2
cascade are responsible. VO2peak in NSCLC patients is
likely principally governed by poor cardiovascular O2
delivery and oxidative capacity as well as unfavorable
fiber type distribution and muscle atrophy/weakness sim-
ilar to the limitations to exercise described in patients
with chronic obstructive pulmonary disease (COPD).
Major contributors to skeletal muscle dysfunction in
NSCLC likely include direct skeletal myopathy (from the
use of oral corticosteroids), deconditioning (from physi-
cal inactivity), and high levels of systemic inflammation
(from underlying disease and therapy)[23].
Importantly, aerobic training will cause favorable adap-
tations in most O2 transport components but will not
reverse skeletal muscle atrophy/weakness and will only
partially reverse a more glycolytic fiber type distribution.
Thus, aerobic training alone may be insufficient to ame-
liorate skeletal muscle dysfunction likely manifest in
NSCLC. Standard resistance training (i.e., activity involv-
ing the acute exertion of force) performed according to
standard guidelines (i.e., 2-5 times/week, 50%-80% of 1
repetition maximum for 12-24 weeks) is unequivocally
acknowledged as the most effective method to improve
skeletal muscle function in human subjects [24-28].
Moreover, in severely deconditioned adults, resistance
training causes improvements in VO2peak  [29-34]
although the mechanisms underlying this effect are not
clearly understood. In theory, while aerobic and resis-
tance training might independently improve VO2peak in
NSCLC, such improvements are likely to be modest
(~10%). Instead, the combination of aerobic and resis-
tance training may be the most effective form of exercise
training to optimally augment VO2peak. The complemen-
tary physiologic adaptations from the combination
approach will result in higher cardiovascular O2 delivery,
skeletal muscle oxidative phosphoryation, muscleJones et al. BMC Cancer 2010, 10:155
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strength and optimal fiber type composition leading to
higher muscle endurance, reduced fatiguability, a higher
threshold to the metabolic waste products of exercise,
and reduced ventilatory requirements during exercise.
This approach is hypothesized to maximize physiologic
adaptations in the principal factors underlying poor
VO2peak in postsurgical NSCLC patients more effectively
than either exercise modality alone (Figure 1).
Against this background, we designed the Lung Cancer
Exercise Training Study (LUNGEVITY), a randomized
trial to investigate the efficacy of different types of exer-
cise training in post-operative NSCLC patients. The fun-
damental rationale for this single-center trial is to identify
the optimal type of exercise training to improve VO2peak
in postoperative NSCLC patients and understand the
physiologic mechanisms underlying this effect. The spe-
cific aims are: (1) to compare the effects of aerobic train-
ing alone, resistance training alone, or both, relative to
attention-control, on VO2peak, (2) determine the effects
on the mechanisms that govern VO2peak (measurements
of the heart-lung-skeletal muscle axis), and (3) to com-
pare the effects on PROs.
Table 1: Subject Eligibility Criteria
Inclusion Criteria
At least 21 years old.
An interval of at least 6 months following surgical resection. VO2peak has been shown to (spontaneously) recover, to a limited degree, 
immediately following (~3 months) and stabilize at ~6 months post 
pulmonary resection. Thus, to accurately determine the effects of exercise 
training on VO2peak in this setting, we felt it was critically important to initiate 
study procedures (i.e., recruit and randomize patients) once changes in 
VO2peak have stabilized to minimize the effects of natural postsurgical 
recovery on improvements in VO2peak,
An interval of no longer than 36 months post-resection
Karnofsky performance status of at least 70% at study entry
Estimated life expectancy of ≥6 months
Ability to read and understand English
Primary attending oncologist approval
Sedentary Patients not performing regular exercise. Regular exercise is defined as ≥5 
days a week, ≥30 minutes each session, at a moderate or vigorous intensity for 
the past month).
Willingness to be randomized
Signed informed consent prior to initiation of study-related 
procedures
Reside within driving distance of DUMC, as necessitated by 
the clinic-based assessments and supervised exercise 
training interventions
Exclusion Criteria
Presence of a concurrent, actively treated other malignancy 
or history of other malignancy treated within the past 3 
years (other than non-melanoma skin cancer)
Presence of metastatic disease
Scheduled to receive any form of adjuvant cancer therapy
Contraindications to maximal exercise testing as 
recommended by the American Thoracic Society and 
exercise testing guidelines for cancer patients
Figure 1 Hypothesized effects of aerobic training alone, resis-
tance training alone, and aerobic plus resistance training on the 
components of the oxygen cascade and resultant impact on exer-
cise tolerance (VO2peak).
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Methods/Design
Participants and Setting
In LUNGEVITY, we will recruit and randomize 160 sub-
jects (40 patients/study arm) with histologically con-
firmed stage I-IIIA NSCLC following curative-intent
complete surgical resection at Duke University Medical
Center (DUMC). The DUMC institutional review board
approved the study and written informed consent will be
obtained from all participants prior to initiation of any
study procedures. Additional inclusion and exclusion cri-
teria are described in Table 1.
Procedures
The study will be conducted in accordance with the
CONSORT (Consolidated Standards of Reporting Trials)
statement for non-pharmacologic interventions[35]. The
study flow is presented in Figure 2. Using a 4-arm, ran-
domized design, potential subjects will be identified and
screened for eligibility by the study research coordinators
via medical record review of NSCLC patients scheduled
to attend a 'follow-up' consultation at DUMC as per stan-
dard of care. Following the consultation and primary
attending oncologist approval, potential eligible subjects
will be provided with a thorough review of the study by
the study coordinators and asked if they are willing to
participate. Interested participants will be provided with
the study consent and baseline study questionnaire. Two
to five days following the consultation, interested partici-
pants will be contacted by telephone by the study coordi-
nators to answer any questions and to schedule the
baseline assessment visit. In addition, to broaden recruit-
ment efforts, subjects previously diagnosed with stage I-
IIIA NSCLC within 36 months of diagnosis will be identi-
fied through the DUMC tumor registry. Permission to
contact potential subjects will be obtained from their
attending oncologist and letters of study invitation
describing the study co-signed by the principal investiga-
tor and attending oncologist will be mailed to all potential
subjects. Interested participants will be able to call a toll-
free telephone number to obtain more information about
study participation.
At the baseline study visit, all participants will complete
the following assessments in order of presentation: (1)
fasting blood draw, (2) pulmonary function test (3) car-
diopulmonary exercise test, and (4) echocardiogram at
rest and exercise. On the following day, patients will per-
form the following assessments: (1) one repetition maxi-
mum lower extremity strength test, and (2) tissue biopsy
of the vastus lateralis. Participants will be asked to adhere
to a water-only fast for 8 hours prior to testing on both
Figure 2 Study Flow.
Potentially eligible patients attending post-surgical ‘follow-up’ 
consultation at DUMC
Interested participants scheduled for baseline assessment
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days. All baseline assessments will be repeated at the end
of the intervention (i.e., 16 weeks). To maximize internal
validity, study endpoint assessments will be conducted by
the same personnel, with the same equipment, in the
same order (timing) at baseline and follow-up timepoints.
Group Allocation (Randomization)
Following the successful completion of baseline assess-
ments, participants will be randomly allocated, on an
individual basis, to one of the three exercise interventions
(i.e., aerobic training, resistance training, the combina-
tion of aerobic and resistance training) or an attention-
control group. Randomly allocated participants will
remain in the same group for the entire duration of the
intervention (i.e., no cross-over). To ensure randomized
groups are similar at baseline, patient randomization will
be stratified based on gender (men vs. female) and smok-
ing status (current vs. non-smoking). For each gender-
smoking status participant subgroup, a computer-gener-
ated list of random treatment assignments will be created
by Dr. Peterson (trial biostatistician) in sequentially num-
bered sealed envelopes. The random allocation
sequences will be concealed from all study personnel
(except Dr. Peterson). A permuted block design with allo-
cation weight of 1:1:1:1 will be used to generate the treat-
ment assignments.
Blinding/Masking
Blinding study participants to treatment allocation in
clinical trials of exercise training is not possible since par-
ticipants are aware whether they are exercising or not.
Also, it is not possible to blind study personnel monitor-
ing exercise training sessions to the participant group
assignment since study personnel are aware whether a
participant is performing aerobic or resistance training.
Nevertheless, all study personnel conducting the study
assessments at baseline and postintervention will be
blinded to treatment assignment for the duration of the
study. Only the trial statistician and the data monitoring
committee will have access to unblinded data, but none
will have any contact with study participants or study
personnel.
Exercise Training Protocols (General Considerations)
The ultimate goal for all exercise training groups will be 3
supervised exercise sessions per week an intensity above
70% of the individually determined VO2peak for aerobic
training and an intensity between 60 and 80% of one-rep-
etition maximum for resistance training, for 30-90 min-
utes/session. All the exercise interventions are designed
such that participants begin exercising at a low intensity
(~50%-60% VO2peak) that is subsequently increased to
more moderate to vigorous intensity (~70%-80% VO2peak)
when appropriate. All interventions will be individually
tailored to each patient following the principles of aerobic
or resistance training prescription guidelines for adults as
recommended by the American College of Sports Medi-
cine (ACSM)[24]. All exercise sessions will also be per-
formed in a supervised setting with one-on-one
supervision by an ACSM-certified exercise physiologist.
Supervised exercise training sessions are critical to
ensure a robust test of exercise training efficacy and
safety in this setting.
All exercise sessions will include a 5-min warm-up and
5-min cool down on either a treadmill or cycle ergometer
at the beginning and end of each training session, respec-
tively. Heart rate and O2 saturation will be monitored
continuously throughout exercise while blood pressure
will be assessed prior, during, and immediately following
each exercise session. To monitor any exercise performed
outside of the supervised sessions, participants will be
provided with a heart rate monitor as well as a study exer-
cise log-book to record all sessions.
Study Arm 1: Aerobic Training Alone
Aerobic training will be prescribed according to ASCM
guidelines and aimed at increasing VO2peak. The ultimate
goal for aerobic training alone is 3 cycle ergometry ses-
sions/week at an intensity above 70% of VO2peak for 30-60
minutes/session. Cycle ergometry was chosen as the
mode of aerobic training because exercise prescriptions
can be more accurately prescribed and monitored on
cycle ergometers than treadmill walking. Also, treadmill
walking requires considerable balance; lung cancer
patients are typically older, have balance issues, and typi-
cally have limited experience with treadmill exercise. Spe-
cific details of the aerobic training prescription are
provided in Table 2.
Study Arm 2: Resistance Training Alone
Resistance training will be prescribed according the
ASCM guidelines and aimed at increasing VO2peak. The
ultimate goal for resistance training alone is 3 resistance
training sessions/week at an intensity above 60% to 80%
of one-repetition maximum (1-RM) for 30-60 minutes/
session (Table 3). Resistance training will be performed
on stationary weight machines (i.e., no free weights).
Patients will be progressively trained to perform three
sets of 8 to 12 repetitions of 8 resistance exercise alternat-
ing between lower and upper body muscle groups.
Study Arm 3: Combined Aerobic and Resistance Training
Combined aerobic and resistance training will be pre-
scribed according the ASCM guidelines and aimed at
increasing VO2peak. The ultimate goal will be three com-
bined exercise sessions per week at an intensity above
60% VO2peak and above 60% 1-RM for aerobic and resis-
tance training, respectively for 30-60 minutes/session.
The general design of the combined intervention is pro-
vided in Table 4 and follows similar intensities to the sin-Jones et al. BMC Cancer 2010, 10:155
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gle modality training. In this arm, the duration of aerobic
training and resistance training will not be added
together but rather the exercise prescription is designed
to exploit the complementary properties of aerobic and
resistance training to optimally improve VO2peak. The
prescription will be balanced to ensure that on days when
aerobic training is prescribed at a high-intensity, resis-
tance training (on the same day) will be conducted at a
lower (easy) intensity and vice versa. This approach will
optimize the desired adaptations without causing exces-
sive fatigue and will help avoid potential interference
effects between aerobic and resistance training.
Attention Control Group (Study Arm 4)
Subjects assigned to the attention-control group will per-
form supervised progressive stretching matched to the
exercise interventions in terms of program length (i.e., 16
weeks), social interaction (participants will receive one-
on-one instruction), and duration (30-45 mins/session).
The progressive stretching program will be prescribed
according the ASCM guidelines for older adults and
aimed at increasing whole-body flexibility. The ultimate
goal for the progressive stretching program is 3 stretching
sessions/week for 30-60 minutes/session for 16 weeks
(Table 5). Stretching will be performed supine on stretch-
ing mats (i.e., no machines). Patients will be progressively
trained to perform 8 stretching exercises alternating
between lower and upper body muscle groups/joints.
Adherence Considerations
To maximize adherence, several strategies will be
employed including individualized attention at the inter-
vention sessions, telephone calls following missed ses-
sions, individuals meetings to outline goals and providing
feedback on study progress. In addition, participants will
be asked to perform 3 supervised exercise/stretching ses-
sions per week over a 7-day period, and will be allowed to
make-up missed sessions within the 16-week study
period. Also, participants will be allowed to schedule
supervised exercise training sessions at anytime from 7
am to 7 pm. This degree of scheduling flexibility allows
participants to perform exercise training sessions at a
convenient time and work around other competing
demands such as medical appointments, work, and fam-
ily commitments. Finally, the study team, consisting of
the PI, the exercise physiologist and study coordinator,
will also meet on a weekly basis to review each partici-
pant's adherence with weekly program goals.
Study Endpoints and Assessments
Table 6 outlines the study assessment schedule while a
brief description of study endpoints and endpoint assess-
ments including sub-studies is provided in Table 7.
Primary Endpoint
VO2peak will be evaluated using a physician-supervised
incremental cycle ergometer test with 12-lead ECG mon-
itoring (Mac® 5000, GE Healthcare) will be performed by
Table 2: Aerobic Training Alone Program
Supervised Aerobic Training
Training Phase Week Weekly Sessions Duration (min/
session)
       Intensity (% of 
               VO2peak)
Introductory 0-4 2-3 15-25 50-60
Intermediate 5-8 3 20-30 60-70
Maintenance 9-16 3 25-45 ≥70
*Weeks intervals shown are goals and may vary for individual patients; All exercise sessions must be performed in a supervised setting.
Table 3: Resistance Training Alone Program
Supervised Resistance Training
Training Phase Week Weekly Sessions Sets, n Repetitions, n Weight, 
maximum 
repetitions
Introductory 0-4 2-3 1-2 8-12 12
Intermediate 5-8 3 2-3 8-12 12
Maintenance 9-16 3 3 8-10 10
*Weeks intervals shown are goals and may vary for individual patients; All exercise sessions must be performed in a supervised setting.Jones et al. BMC Cancer 2010, 10:155
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ACSM-certified exercise physiologists blinded to the
patient's randomization group. Expired gases will be ana-
lyzed continuously by a metabolic measurement system
(ParvoMedics TrueMax, Sandy, UT). Subjects will begin
pedaling at 20 Watts for one minute and is increased 5 to
20 Watts every minute until exhaustion or a symptom-
limited VO2peak is achieved. This protocol has been previ-
ously demonstrated to be appropriate for measuring
VO2peak  in our prior studies among NSCLC
patients[18,36-38]. Exercise will be terminated if any
ECG abnormalities are observed.
Secondary Endpoints
Patient Reported Outcomes will include QOL, fatigue,
dyspnea, and depression. QOL will be assessed using the
Functional Assessment of Cancer Therapy - Lung (FACT-
L) scale developed for the assessment of patient symp-
toms and QOL in lung cancer patients [39]. The FACT-L
contains four subscales for physical (7-items), functional
(7-items), emotional (6-items), social/family (7-items)
well-being plus a lung cancer specific subscale (15-items)
which will be summed to obtain the FACT-L score (all 42
items). Fatigue will be assessed using the 13-item FACT-
fatigue scale for the assessment of fatigue in cancer
patients[40]. Dyspnea will be assessed using the Cancer
Dyspnea Scale (CDS)[41]. The CDS is a 12-item scale
comprised of three factors (sense of sense/sense of anxi-
ety/sense of discomfort). This instrument has been dem-
onstrated to be a brief, valid, and feasible scale for
assessing cancer-related dyspnea among inoperable
NSCLC patients[42,43]. Finally, depression  will be
assessed using the Center for Epidemiologic Studies
Depression scale (CES-D)[44]. We have found these
instruments to be reliable, valid, responsive, brief, and
easy to administer in our on-going study and prior
reports in lung cancer patients.
Physiologic Mechanisms of VO2peak will include pul-
monary function, cardiovascular O2 delivery, and skeletal
muscle function. Pulmonary Function will be determined
using standard spirometry to assess FEV1. All measures
will be performed in a sitting position according to the
American Thoracic Society guidelines [45]. Cardiovascu-
lar O2Delivery will be comprised of: (1) Cardiac Output:
Left ventricular volumes will be performed with a com-
mercially available ultrasound system (GE Vivid 7 or
Philips i33). Apical two- and four- chamber views will be
assessed at rest and exercise to determine left ventricular
end-diastolic volume and end-systolic volume by modi-
fied Simpson's rule [46,47]. Stroke volume will be calcu-
lated as end-diastolic volume minus end-systolic volume.
Cardiac output will be calculated by stroke volume multi-
plied by heart rate, (2) Hemoglobin (Hb) Concentration
(O2 carrying capacity of blood) will be assessed via a
venous blood draw according to standard guidelines.
Normal range for hemoglobin is ~13 - 18 grams per deci-
Table 4: Combined Aerobic and Resistance Training Program
Aerobic Training Resistance Training
Training 
Phase
Wk* Weekly 
Sessions
Duration 
(min/
session)
Intensity of 
VO2peak
Duration 
(min/
session)
Sets, n Repetitions, n Weight, max 
repetitions
Introductory 0-4 2 15-25 50-60 15-20 1 8-12 12
Intermediate 5-9 3 20-30 >70 ~25 2 8-12 12
Maintenance 10-24 3 30-45 >70 ~30 2 8-10 10
*Week intervals shown are goals and may vary for individual patients. All exercise sessions must be performed in a supervised setting.
Table 5: Attention Control Program
Supervised Aerobic Training
Training Phase Week Weekly Sessions Duration (min/
session)
Duration of each 
Stretch (mins)
Introductory 0-4 2-3 15-25 1-2
Intermediate 5-8 3 20-30 2-5
Maintenance 9-16 3 25-45 ≥5
*Weeks intervals shown are goals and may vary for individual patients; All exercise sessions must be performed in a supervised setting.Jones et al. BMC Cancer 2010, 10:155
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liter for men and 12 - 16 for women. Mean cell Hb
(amount of Hb/red blood cell) and platelet count (num-
ber of platelets in blood volume) will also be calculated,
and (3) Arterial O2 Saturation will be assessed at rest and
continuously during exercise using pulse oximetry (Biox
3700, Ohmeda Medical, Boulder, CO), which provides
the most accurate noninvasive assessment of blood arte-
rial O2 saturation levels. Pulse oximetry works on the
principle of the red and infrared light absorption charac-
teristics of oxygenated and deoxygenated Hb. Normal
range is 96% to 100% at sea level for healthy humans.
Skeletal Muscle Function will be determined by: (1)
Fiber Type Distribution w i l l  b e  d e t e r m i n e d  b y  t i s s u e
biopsy of the vastumus laterialis using a modified Berg-
strom needle technique [48]. Biopsy sites will be first
anesthetized with a 2% lidocaine solution. Next, a 0.5 cm
incision will be made through the skin and fascia lata. All
samples will be prepared immediately by weighing and
then dividing the samples for subsequent analysis as pre-
viously described[48]. A portion will be mounted in
cross-section in optimal temperature compound (OCT)
media immediately prior to being frozen in isopentane
cooled by liquid nitrogen for fiber type determination.
Specifically, myosin heavy-chain (MHC) isoforms I, IIa,
a n d  I I x  w i l l  b e  i d e n t i f i e d  b y  o r d e r  o f  m i g r a t i o n  a s
described by Duscha et al [48]. Gels will be scanned elec-
tronically, and relative proportions of MHC isoform will
be measured using NIH image 1.60 for Macintosh and
Jandel PeakFit for Windows, (2) Oxidative Capacity
(Enzymology) will be assessed via maximal activities of
several oxidative pathways representative of different
energy pathways using frozen tissue samples as previ-
ously described [48]. Phosphofructokinase and succinic
dehydrogenase activities will be performed on fresh
homogenates while the enzymes malate dehydrogenase
and 3-hydoxyl-Co-A dehydrogenase will be performed on
the frozen homogenates stored at -80°C, and (3) Lower
Extremity Maximal Muscular Strength will be assessed as
a voluntary one-repetition maximum (1-RM) using the
following exercises: (1) leg press, (2) leg extension, and (3)
leg curl. These tests will be repeated twice and the heavi-
est weight lifted while adhering to strict technique and
form will be used as the score.
Tracking and Monitoring of Adverse Events
Tracking and monitoring of adverse events will be
assessed using the following methods: (1) during inter-
vention sessions, all patients will receive one-on-one
supervision and all adverse events (e.g., knee pain, back
pain) will be recorded on the patient case report form
(CRF). In addition, heart rate, blood pressure, and O2 sat-
uration will be recorded prior to, during, and following
every intervention session, (2) at the beginning of each
week, the exercise physiologist will spend the first 10
Table 6: Study Assessment Schedule
Baseline Postintervention (16 weeks)
Assessment Screening Day 0 Day 1 Day 2 Day 3-5 Day 112 Day 113
Chart Review x
Patient Approached x
Informed Consent x
Day 1 Testing
Blood draw x x
Body Composition x x
Pulmonary 
Function
xx
CPET x x
Echocardiogram x x
Day 2 Testing
Strength testing x x
Muscle biopsy x x
Day 3 Testing
Repeat CPET x
Randomization x
Intervention 
initiation
xJones et al. BMC Cancer 2010, 10:155
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minutes of every session discussing any potential negative
side-effects of the intervention assignment and any inju-
ries that may have occurred. All events will be recorded
in the patient CRF, (3) every six months a meeting of all
investigators will be scheduled to review and discuss all
reported non-serious and serious adverse events for early
identification of negative issues and development of solu-
tions. All serious adverse events will be immediately
reported to Duke IRB and immediately circulated to all
study investigators for appropriate discussion, and (4)
early stopping rules in response to a differential higher
frequency of adverse events in a particular study group.
Statistical Considerations
Sample Size Calculation
This randomized phase II trial will accrue 160 subjects
with postsurgical NSCLC over an accrual period of ~48
months. For each of the primary and secondary end-
points, three separate t-tests will be used to compare each
experimental arm to the control arm in mean change
across time of the endpoint. For each endpoint, the over-
all alpha level will be controlled at a two-sided 0.05 by
using Holm's procedure[49]. That is, Holm's procedure
first ranks the three p-values from lowest to highest. The
first (lowest) p-value has to be less than 0.05/3 (0.0167) to
be significant and permit continuation to the other t-
tests. The Holm's procedure continues sequentially in
this fashion using alpha levels of 0.05/2 (0.025) and 0.05/1
(0.05) for the remaining two t-tests, respectively. Power
for this study is defined as the probability that at least one
of the three t-tests of the arm effect on VO2peak is signifi-
cant; in other words, power is the probability that the first
of the 3 ordered t-tests are significant. We assume that
change in VO2peak will have a standard deviation of 3.0
mL.kg.-1min-1 as observed in our pilot work. Statistical
power depends upon the configuration of mean change in
VO2peak across the 4 arms. Thus, for example, 80% power
i s  o b t a i n e d  w h e n  t h e  m e a n  c h a n g e  i n  V O 2peak  across
Arms 1, 2, 3, and 4 is 0.60, 0.60, 2.10, and 0.0 (mL.kg.-
1min-1), respectively.
Analytic Plan
The principal analysis of the study endpoints will employ
the intention-to-treat (ITT) approach. The ITT analysis
will include all randomized participants in their ran-
domly assigned allocation. The intervention group
assignment will not be altered based on the participant's
adherence to the randomly allocated study arm. Patients
who are lost-to-follow-up will be included in all primary
and secondary analyses by assuming zero change across
time. For the primary analysis, a multiple regression
model will be used to regress change in VO2peak on study
group, the baseline value of the endpoint, and other perti-
nent baseline variables that may influence change in the
study endpoints (e.g., co-morbid conditions/medications,
self-reported exercise history, age).
Discussion
Methodological Considerations
Several issues were considered when designing LUN-
GEVITY. First, was the decision to investigate exercise in
patients with operable (early) or inoperable (advanced)
NSCLC. The majority of patients (~75%) diagnosed with
NSCLC present with inoperable (advanced) disease.
From a population health perspective, exercise trials in
inoperable disease are likely to greater impact in compar-
Table 7: Study Measurements and Sub-Studies
Physical measurements and tests
Height, weight, and body mass index
Body composition
Resting and exercise heart rate
Resting and exercise blood pressure
Resting and exercise 12-lead ECG
Peak and submaximal oxygen consumption
Ventilatory threshold
Mechanistic physiological measurements
Resting and exercise echocardiogram
Skeletal muscle function (fiber type distribution, oxidative 
capacity, and muscular strength)
Pulmonary function
Hemoglobin concentration
Resting and exercise oxygen saturation
Each intervention (exercise or attention control) session: 
heart rate, blood pressure, oxygen saturation, RPE
Patient-reported outcomes (questionnaire-based)
Medications
Quality of life
Fatigue
Dyspnea
Depression
Adverse events (Common Terminology Criteria for Adverse 
Events; CTCAE v.4.0)
Substudies
Genetic studies to examine differences to exercise stimulus
Predictors of exercise adherence
Pilot studies for exercise-induced changes in peripheral 
gene expressionJones et al. BMC Cancer 2010, 10:155
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ison to those in patients with operable disease. Our deci-
sion to target early-stage patients was based on several
important factors, primarily, exercise training safety and
patient eligibility (recruitment). Inoperable NSCLC
patients have poor prognosis and commonly present with
significant smoking-related comorbid disease, advanced
disease and symptoms, and are heavily treated with
aggressive chemotherapy and concurrent radiotherapy
[37]. As a result, the majority present with KPS scores
<70% which may preclude participation in a moderate-
intensity exercise training program and increase the risk
of an exercise-related adverse [37]. Accordingly, it is pru-
dent to focus on patients with operable disease; these
patients have, in general, better performance status (and
prognosis) and issues of NSCLC survivorship are becom-
ing increasingly important aspect of multidisciplinary
care. A second important consideration was the decision
to investigate the efficacy of exercise following comple-
tion of, as opposed to, during adjuvant therapy. In our
pilot work, aerobic training was associated with a 2% and
11% improvement in VO2peak among patients receiving or
not receiving chemotherapy, respectively for postopera-
tive NSCLC[17]. Clearly, without a non-intervention con-
trol group, it is not known whether maintenance of
VO2peak during chemotherapy is important. Nevertheless,
given the lack of benefit of exercise training during che-
motherapy, subjects in LUNGEVITY will be recruited ≥6
months following the completion of adjuvant therapy, if
appropriate.
Ancillary Studies
A number of ancillary studies are planned for LUNGEV-
ITY. First, as part of the informed consent process, a sam-
ple of white cells (buffy coat) will be collected from each
subject in order to conduct genetic studies. A question of
great interest that has not yet been addressed in the can-
cer populations is assessing genetic contributions to
inter-individual differences in response to exercise train-
ing. Second, we will conduct ancillary study to examine
predictors of adherence to the interventions as well as
extent of exercise 'drop-in' in the attention control group
across different exercise protocols in NSCLC. To address
this question, we will adopt the guiding principles of the
theory of planned behavior (TPB)[50]. This data will be
used to inform the design and implementation of future
trials. Third, in addition to assessing the physiological
mediators of the exercise - VO2peak relationship, LUN-
GEVITY also provides a unique opportunity to examine
which psychological variables that may mediate the exer-
cise - PROs relationship. To this end, we will assess
whether self-efficacy, affect, and social support mediate
the effect of the exercise interventions and attention-con-
trol on anticipated improvements in PROs. Finally, we
will include pilot studies to investigate the effects of exer-
cise training on changes in peripheral gene expression
(from analysis of whole blood mRNA) using high-density
mRNA microarrays. Such studies will provide insight into
the molecular mechanistic properties of exercise in
NSCLC.
Summary
The past decade has witnessed a dramatic increase in
clinical and research interest of the application of exercise
following a cancer diagnosis [51-58]. Recent systematic
reviews conclude that exercise is a safe and feasible sup-
portive intervention to improve symptom control and
cardiorespiratory fitness in cancer patients with early-
stage disease either during or following the completion of
adjuvant therapy [59-63]. Moreover, recent observational
studies provided the first evidence that regular exercise
(i.e., 30 minutes of brisk walking at least 5 days/week)
may be associated with substantial reductions in cancer-
specific mortality and all-cause mortality among patients
with early breast and colorectal cancer following the
completion of adjuvant therapy [64-68]. Despite this
growing evidence, investigation of the role of exercise
training following a diagnosis of NSCLC remains limited.
The pathophysiology of NSCLC together with conven-
tional therapeutic management is associated with unique
and varying degrees of adverse physiological impairments
that dramatically reduce patient's ability to tolerate exer-
cise. Poor VO2peak likely predisposes to increased suscep-
tibility to other common age-related diseases, greater
symptoms, poor QOL, and even premature death. In
r e c e n t  y e a r s ,  a  l i m i t e d  n u m b e r  o f  p i l o t  s t u d i e s  h a v e
emerged that provide 'proof-of-principle' that supervised
aerobic training is a safe and feasible supportive interven-
tion associated with improvements in cardiopulmonary
function and select patient -reported outcomes in post -
surgical NSCLC. In addition, VO2peak may be a strong,
independent predictor of long-term all-cause mortality in
this population. Against this background, LUNGEVITY
was designed to identify the most effective type of exer-
cise training to improve VO2peak  and to elucidate the
physiologic mechanisms underlying this improvement.
To our knowledge, LUNGEVITY will be the first trial to
compare different types of exercise training protocols in
NSCLC as well as the first to study the effects of exercise
on changes in the organ components that govern exercise
tolerance in any cancer population. In totality, LUNGEV-
ITY will address many critical unanswered questions
regarding the role and mechanistic properties of exercise
in NSCLC and will set the stage for more definite trials.
In the long-term, we hope that this research will contrib-
ute to the establishment of clinical exercise therapy reha-
bilitation guidelines for patients across the entire NSCLC
continuum.Jones et al. BMC Cancer 2010, 10:155
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